- Home
- VRAR vs GDTC Comparison
VRAR vs GDTC Comparison
Compare VRAR & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- GDTC
- Stock Information
- Founded
- VRAR 2016
- GDTC 2018
- Country
- VRAR United States
- GDTC Singapore
- Employees
- VRAR N/A
- GDTC N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- GDTC Health Care
- Exchange
- VRAR Nasdaq
- GDTC Nasdaq
- Market Cap
- VRAR 33.3M
- GDTC 28.0M
- IPO Year
- VRAR 2021
- GDTC 2023
- Fundamental
- Price
- VRAR $1.49
- GDTC $2.21
- Analyst Decision
- VRAR Strong Buy
- GDTC Buy
- Analyst Count
- VRAR 1
- GDTC 1
- Target Price
- VRAR $2.62
- GDTC $5.00
- AVG Volume (30 Days)
- VRAR 135.2K
- GDTC 6.6K
- Earning Date
- VRAR 05-15-2025
- GDTC 01-01-0001
- Dividend Yield
- VRAR N/A
- GDTC N/A
- EPS Growth
- VRAR N/A
- GDTC N/A
- EPS
- VRAR N/A
- GDTC N/A
- Revenue
- VRAR $8,756,789.00
- GDTC $368,838.00
- Revenue This Year
- VRAR $23.96
- GDTC $5.37
- Revenue Next Year
- VRAR $12.15
- GDTC N/A
- P/E Ratio
- VRAR N/A
- GDTC N/A
- Revenue Growth
- VRAR N/A
- GDTC N/A
- 52 Week Low
- VRAR $0.50
- GDTC $1.20
- 52 Week High
- VRAR $7.00
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- VRAR 52.95
- GDTC 49.36
- Support Level
- VRAR $1.31
- GDTC $2.09
- Resistance Level
- VRAR $1.38
- GDTC $2.35
- Average True Range (ATR)
- VRAR 0.11
- GDTC 0.10
- MACD
- VRAR 0.01
- GDTC 0.00
- Stochastic Oscillator
- VRAR 66.67
- GDTC 50.00
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.